Group 1 - The core point of the news is that Hongbo Pharmaceutical's stock has risen by 7.01% on January 12, reaching a price of 44.13 yuan per share, with a total market capitalization of 6.16 billion yuan, and a cumulative increase of 29.32% over the past three days [1] - Hongbo Pharmaceutical, established on December 14, 2007, focuses on drug discovery, pharmaceutical process research and development, and the commercial production of raw material intermediates, with revenue composition of 52.67% from drug discovery, 35.00% from commercial production, 8.10% from process research and development, and 4.23% from other sources [1] Group 2 - Longcheng Fund's Longcheng Consumption Value Mixed A Fund (200006) holds 1.601 million shares of Hongbo Pharmaceutical, representing 2.08% of the circulating shares, with a floating profit of approximately 4.6267 million yuan today and a total floating profit of 14.9687 million yuan over the past three days [2][3] - The Longcheng Consumption Value Mixed A Fund has a total scale of 516 million yuan, with a year-to-date return of 17.29%, ranking 26 out of 9012 in its category, and a one-year return of 40.7%, ranking 3084 out of 8157 [2] - The fund manager, Long Yufei, has been in position for 8 years and 89 days, with the best fund return during his tenure being 61.42% and the worst being -8.9% [2]
泓博医药股价涨7.01%，长城基金旗下1只基金重仓，持有160.09万股浮盈赚取462.67万元